Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study (CROSBI ID 151290)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Francetić, Igor ; Kalenić, Smilja ; Huić, Mirjana ; Merčep, Iveta ; Makar-Aušperger, Ksenija ; Likić, Robert ; Erdeljić, Viktorija ; Tripković, Vesna ; Šimić, Petra Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study // Croatian medical journal, 49 (2008), 2; 207-214. doi: 10.3325/cmj.2008.2.207

Podaci o odgovornosti

Francetić, Igor ; Kalenić, Smilja ; Huić, Mirjana ; Merčep, Iveta ; Makar-Aušperger, Ksenija ; Likić, Robert ; Erdeljić, Viktorija ; Tripković, Vesna ; Šimić, Petra

engleski

Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study

To determine the effect of aminoglycoside cycling in six tertiary intensive care units (ICU) on the rates of sepsis, aminoglycoside resistance patterns, antibiotic consumption, and costs. This was a prospective longitudinal interventional study that measured the effect of change from first-line gentamicin usage (February 2002-February 2003) to amikacin usage (February 2003-February 2004) on the aminoglycoside resistance patterns, number of patients with gram-negative bacteremia, consumption of antibiotics, and the cost of antimicrobial drugs in 6 tertiary care ICUs in Zagreb, Croatia. The change from first-line gentamicin to amikacin usage led to a decrease in the overall gentamicin resistance of gram-negative bacteria (GNB) from 42% to 26% (P<0.001 ; z-test of proportions) and netilmicin resistance from 33% to 20% (P<0.001), but amikacin resistance did not change significantly (P=0.462), except for Acinetobacter baumanni (P=0.014). Sepsis rate in ICUs was reduced from 3.6% to 2.2% (P<0.001 ; chi(2) test), with a decline in the number of nosocomial bloodstream infections from 55/100 patient-days to 26/100 patient-days (P=0.001, chi(2) test). Furthermore, amikacin use led to a 16% decrease in the overall antibiotic consumption and 0.1 euro/patient/d cost reduction. Exclusive use of amikacin significantly reduced the resistance of GNB isolates to gentamicin and netilmicin, the number of GNB nosocomial bacteremias, and the cost of total antibiotic usage in ICUs

aminoglycoside; cycling; tertiary intensive care units; longitudinal interventional study

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

49 (2)

2008.

207-214

objavljeno

0353-9504

10.3325/cmj.2008.2.207

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost